Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB, a specialty pharma company, today announces that the NEFIGAN Trial of Nefecon for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint.

14 Apr 2015

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets.

31 Mar 2015

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia).

31 Mar 2015

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Use of angiotensin system inhibitors is associated with significant survival benefits in metastatic renal cell carcinoma patients treated in the targeted therapy era, research findings indicate.

25 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

Mechanistic subtypes of IPAH revealed

Researchers have provided evidence for distinct processes underlying vasodilator-responsive and nonresponsive idiopathic pulmonary arterial hypertension.

13 Mar 2015

Anticholinergic medications associated with pneumonia risk in older people

Taking commonly used medications with anticholinergic effects is associated with a significantly higher risk for developing pneumonia in a study of more than 3,000 older Group Health patients living in the community--not in nursing homes.

3 Mar 2015

Novartis’ heart failure medicine LCZ696 granted FDA priority review

LCZ696, a twice-a-day medicine being investigated for heart failure, acts to enhance the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).

16 Feb 2015

Research finding could lead to new therapeutic target for treating hypertension in males

Higher levels of a "danger" molecule may be one reason males tend to become hypertensive earlier and more severely than females, scientists say.

16 Feb 2015

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

16 Feb 2015

Mechanistic subtypes of IPAH revealed

Researchers have provided evidence for distinct processes underlying vasodilator-responsive and nonresponsive idiopathic pulmonary arterial hypertension.

13 Feb 2015

Scientists find that treating the uninjured side of brain can maximize stroke recovery

To maximize stroke recovery, researchers may want to focus more on ways to support the side of the brain where the injury didn't occur, scientists report.

13 Feb 2015

Not all ARB drugs are equally effective at treating heart failure, reveals NSU researcher

Millions of people take angiotensin receptor blockers (ARBs) to help treat heart failure. But it turns out not all ARBs are created equally, according to one Nova Southeastern University researcher's findings.

3 Feb 2015

Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on strategies for prescribing drugs to manage obesity and promote weight loss.

16 Jan 2015

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.

30 Dec 2014

Study calls for new protocols to treat women with high blood pressure

That blood pressure plays a role in human health has been known for quite a while. Hypertension - the medical term for high blood pressure - was first described as a disease in the early 1800s, and the inflatable cuff that's used in measuring blood pressure was invented in 1896.

10 Dec 2014

President of Institute of Medicine to deliver presentation at University of Louisville

The president of the Institute of Medicine of the National Academies will present the 2014 Leonard Leight Lecture at the University of Louisville.

2 Dec 2014

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its accomplishments and financial results for the three months ended September 30, 2014.

29 Nov 2014

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear in the New England Journal of Medicine.

21 Nov 2014

Investigational treatment shows promise against Marfan syndrome

An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta.

18 Nov 2014

Angiotensin News and Research

Further Reading

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

New oral drug shows promise in patients with chronic kidney disease

Angiotensin system inhibitor use improves metastatic RCC survival outcomes

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Mechanistic subtypes of IPAH revealed

Anticholinergic medications associated with pneumonia risk in older people

Novartis’ heart failure medicine LCZ696 granted FDA priority review

Research finding could lead to new therapeutic target for treating hypertension in males

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Mechanistic subtypes of IPAH revealed

Scientists find that treating the uninjured side of brain can maximize stroke recovery

Not all ARB drugs are equally effective at treating heart failure, reveals NSU researcher

Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Study calls for new protocols to treat women with high blood pressure

President of Institute of Medicine to deliver presentation at University of Louisville

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Investigational treatment shows promise against Marfan syndrome

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News